We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness of brentuximab vedotin before and after allogeneic stem‐cell transplantation in the management of transformed mycosis fungoides.
- Authors
André, R.; Ram‐Wolff, C.; Battistella, M.; Peffault de Latour, R.; Petit, A.; Bouaziz, J.D.; Brice, P.; Bagot, M.; Masson, A.
- Abstract
Dear Editor, Brentuximab vedotin (BV) is an antibody-drug conjugate, composed of a humanized anti-CD30 IgG1 and the antimitotic monomethyl auristatine E.[1] The interest of BV in the management of CD30 SP + sp mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (ALCL) has recently been demonstrated compared with methotrexate or bexarotene.[2] The expression of the CD30 receptor (tumour necrosis factor receptors family) by these T-cell lymphomas has been known since 1985.[3] It is not constant in MF and is more frequent in transformed disease.[1] BV may also be efficient in MF without any expression of CD30[4] and has been used in combination with bendamustine in transformed Sézary syndrome.[5] Finally, it can be used as a bridge to allogeneic stem-cell transplantation (ASCT) in relapsed or refractory non-Hodgkin lymphoma.[6] Can BV be resumed after ASCT? It is used in the consolidation treatment of Hodgkin lymphoma,[7] and has been studied in patients with CD30 SP + sp Hodgkin lymphoma or systemic ALCL who relapsed after achieving complete or partial remission with initial BV therapy,[8] but there is a lack of available data in primary cutaneous T-cell lymphomas. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
- Subjects
CUTANEOUS T-cell lymphoma; MYCOSIS fungoides; HODGKIN'S disease; TRANSPLANTATION of organs, tissues, etc.; CORE needle biopsy
- Publication
British Journal of Dermatology, 2020, Vol 182, Issue 6, p1503
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.18806